Olorinab

Olorinab
Olorinab structure.png
Clinical data
Routes of
administration
Oral
Identifiers
CAS Number
PubChem CID
KEGG
Chemical and physical data
FormulaC18H24N5O3
Molar mass358.422 g·mol−1
3D model (JSmol)

Olorinab (APD371) is a drug being developed by Arena Pharmaceuticals for the treatment of gastrointestinal pain associated with Crohn's disease and irritable bowel syndrome.[1] It acts as a potent and selective cannabinoid CB2 receptor agonist and is claimed to be orally active and peripherally selective.[2][3] Initial Phase IIa exploratory clinical trials have been successful,[4] with Phase IIb trials projected to start in 2019.[5]

See also[edit]

References[edit]